{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:08:15Z","timestamp":1793412495112,"version":"4.5.0"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2003,6,1]]},"DOI":"10.1038\/nm0603-669","type":"journal-article","created":{"date-parts":[[2003,5,30]],"date-time":"2003-05-30T14:43:39Z","timestamp":1054305819000},"page":"669-676","source":"Crossref","is-referenced-by-count":7880,"title":["The biology of VEGF and its receptors"],"prefix":"10.1038","volume":"9","author":[{"given":"Napoleone","family":"Ferrara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"LeCouter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnm0603669_CR1","doi-asserted-by":"publisher","first-page":"10931","DOI":"10.1016\/S0021-9258(19)49853-0","volume":"267","author":"J Folkman","year":"1992","unstructured":"Folkman, J. & Shing, Y. Angiogenesis. J. Biol. Chem. 267, 10931\u201310934 (1992).","journal-title":"J. Biol. Chem."},{"key":"BFnm0603669_CR2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/35025215","volume":"407","author":"GD Yancopoulos","year":"2000","unstructured":"Yancopoulos, G.D. et al. Vascular-specific growth factors and blood vessel formation. Nature 407, 242\u2013248 (2000).","journal-title":"Nature"},{"key":"BFnm0603669_CR3","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nrc909","volume":"2","author":"N Ferrara","year":"2002","unstructured":"Ferrara, N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2, 795\u2013803 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnm0603669_CR4","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/70928","volume":"5","author":"N Ferrara","year":"1999","unstructured":"Ferrara, N. & Alitalo, K. Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 5, 1359\u20131364 (1999).","journal-title":"Nat. Med."},{"key":"BFnm0603669_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/74651","volume":"6","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6, 389\u2013395 (2000).","journal-title":"Nat. Med."},{"key":"BFnm0603669_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1210\/edrv.18.1.0287","volume":"18","author":"N Ferrara","year":"1997","unstructured":"Ferrara, N. & Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev. 18, 4\u201325 (1997).","journal-title":"Endocr. Rev."},{"key":"BFnm0603669_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1096\/fasebj.13.1.9","volume":"13","author":"G Neufeld","year":"1999","unstructured":"Neufeld, G., Cohen, T., Gengrinovitch, S. & Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13, 9\u201322 (1999).","journal-title":"FASEB J."},{"key":"BFnm0603669_CR8","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.1038\/ncb0102-e2","volume":"4","author":"MJ Karkkainen","year":"2002","unstructured":"Karkkainen, M.J., Makinen, T. & Alitalo, K. Lymphatic endothelium: a new frontier of metastasis research. Nat. Cell Biol. 4, E2\u2013E5 (2002).","journal-title":"Nat. Cell Biol."},{"key":"BFnm0603669_CR9","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1126\/science.2479986","volume":"246","author":"DW Leung","year":"1989","unstructured":"Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V. & Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306\u20131309 (1989).","journal-title":"Science"},{"key":"BFnm0603669_CR10","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1002\/j.1460-2075.1989.tb08557.x","volume":"8","author":"J Plouet","year":"1989","unstructured":"Plouet, J., Schilling, J. & Gospodarowicz, D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells. EMBO J. 8, 3801\u20133808 (1989).","journal-title":"EMBO J."},{"key":"BFnm0603669_CR11","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1084\/jem.20021244","volume":"196","author":"JA Nagy","year":"2002","unstructured":"Nagy, J.A. et al. Vascular permeability factor\/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J. Exp. Med. 196, 1497\u20131506 (2002).","journal-title":"J. Exp. Med."},{"key":"BFnm0603669_CR12","first-page":"1","volume":"112 (RE21)","author":"T Matsumoto","year":"2001","unstructured":"Matsumoto, T. & Claesson-Welsh, L. VEGF receptor signal transduction. Science STKE 112 (RE21), 1\u201317 (2001).","journal-title":"Science STKE"},{"key":"BFnm0603669_CR13","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nm721","volume":"8","author":"V Compernolle","year":"2002","unstructured":"Compernolle, V. et al. Loss of HIF-2\u03b1 and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat. Med. 8, 702\u2013710 (2002).","journal-title":"Nat. Med."},{"key":"BFnm0603669_CR14","doi-asserted-by":"publisher","first-page":"13313","DOI":"10.1074\/jbc.273.21.13313","volume":"273","author":"HP Gerber","year":"1998","unstructured":"Gerber, H.P., Dixit, V. & Ferrara, N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem. 273, 13313\u201313316 (1998).","journal-title":"J. Biol. Chem."},{"key":"BFnm0603669_CR15","doi-asserted-by":"publisher","first-page":"30366","DOI":"10.1074\/jbc.273.46.30366","volume":"273","author":"HP Gerber","year":"1998","unstructured":"Gerber, H.P. et al. VEGF regulates endothelial cell survival by the PI3-kinase\/Akt signal transduction pathway. Requirement for Flk-1\/KDR activation. J. Biol. Chem. 273, 30366\u201330343 (1998).","journal-title":"J. Biol. Chem."},{"key":"BFnm0603669_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1172\/JCI5028","volume":"103","author":"LE Benjamin","year":"1999","unstructured":"Benjamin, L.E., Golijanin, D., Itin, A., Pode, D. & Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103, 159\u2013165 (1999).","journal-title":"J. Clin. Invest."},{"key":"BFnm0603669_CR17","doi-asserted-by":"publisher","first-page":"14765","DOI":"10.1073\/pnas.93.25.14765","volume":"93","author":"F Yuan","year":"1996","unstructured":"Yuan, F. et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor\/vascular permeability factor antibody. Proc. Natl. Acad. Sci. USA 93, 14765\u201314770 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm0603669_CR18","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1242\/dev.126.6.1149","volume":"126","author":"HP Gerber","year":"1999","unstructured":"Gerber, H.P. et al. VEGF is required for growth and survival in neonatal mice. Development 126, 1149\u20131159 (1999).","journal-title":"Development"},{"key":"BFnm0603669_CR19","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1084\/jem.172.6.1535","volume":"172","author":"M Clauss","year":"1990","unstructured":"Clauss, M. et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J. Exp. Med. 172, 1535\u20131545 (1990).","journal-title":"J. Exp. Med."},{"key":"BFnm0603669_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0925-5710(95)00412-2","volume":"62","author":"HE Broxmeyer","year":"1995","unstructured":"Broxmeyer, H.E. et al. Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor. Int. J. Hematol. 62, 203\u2013215 (1995).","journal-title":"Int. J. Hematol."},{"key":"BFnm0603669_CR21","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"DI Gabrilovich","year":"1996","unstructured":"Gabrilovich, D.I. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2, 1096\u20131103 (1996).","journal-title":"Nat. Med."},{"key":"BFnm0603669_CR22","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1084\/jem.193.9.1005","volume":"193","author":"K Hattori","year":"2001","unstructured":"Hattori, K. et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp Med. 193, 1005\u20131014 (2001).","journal-title":"J. Exp Med."},{"key":"BFnm0603669_CR23","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/nature00821","volume":"417","author":"H-P Gerber","year":"2002","unstructured":"Gerber, H.-P. et al. Vascular endothelial growth factor regulates hematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417, 954\u2013958 (2002).","journal-title":"Nature"},{"key":"BFnm0603669_CR24","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1126\/science.6823562","volume":"219","author":"DR Senger","year":"1983","unstructured":"Senger, D.R. et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983\u2013985 (1983).","journal-title":"Science"},{"key":"BFnm0603669_CR25","first-page":"1029","volume":"146","author":"HF Dvorak","year":"1995","unstructured":"Dvorak, H.F., Brown, L.F., Detmar, M. & Dvorak, A.M. Vascular permeability factor\/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146, 1029\u20131039 (1995).","journal-title":"Am. J. Pathol."},{"key":"BFnm0603669_CR26","doi-asserted-by":"publisher","first-page":"H687","DOI":"10.1152\/ajpcell.1997.273.2.C687","volume":"273","author":"DO Bates","year":"1997","unstructured":"Bates, D.O. & Curry, F.E. Vascular endothelial growth factor increases microvascular permeability via a Ca(2+)-dependent pathway. Am. J. Physiol. 273, H687\u2013H694 (1997).","journal-title":"Am. J. Physiol."},{"key":"BFnm0603669_CR27","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1242\/jcs.108.6.2369","volume":"108","author":"WG Roberts","year":"1995","unstructured":"Roberts, W.G. & Palade, G.E. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci. 108, 2369\u20132379 (1995).","journal-title":"J. Cell Sci."},{"key":"BFnm0603669_CR28","first-page":"H586","volume":"265","author":"DD Ku","year":"1993","unstructured":"Ku, D.D., Zaleski, J.K., Liu, S. & Brock, T.A. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am. J. Physiol. 265, H586\u2013H592 (1993).","journal-title":"Am. J. Physiol."},{"key":"BFnm0603669_CR29","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1097\/00005344-199606000-00011","volume":"27","author":"R Yang","year":"1996","unstructured":"Yang, R. et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J. Cardiovasc. Pharmacol. 27, 838\u2013844 (1996).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"BFnm0603669_CR30","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1210\/mend-5-12-1806","volume":"5","author":"KA Houck","year":"1991","unstructured":"Houck, K.A. et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5, 1806\u20131814 (1991).","journal-title":"Mol. Endocrinol."},{"key":"BFnm0603669_CR31","doi-asserted-by":"publisher","first-page":"11947","DOI":"10.1016\/S0021-9258(18)99049-6","volume":"266","author":"E Tischer","year":"1991","unstructured":"Tischer, E. et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266, 11947\u201311954 (1991).","journal-title":"J. Biol. Chem."},{"key":"BFnm0603669_CR32","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/0006-291X(89)92678-8","volume":"161","author":"N Ferrara","year":"1989","unstructured":"Ferrara, N. & Henzel, W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161, 851\u2013858 (1989).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnm0603669_CR33","doi-asserted-by":"publisher","first-page":"26031","DOI":"10.1016\/S0021-9258(18)35712-0","volume":"267","author":"KA Houck","year":"1992","unstructured":"Houck, K.A., Leung, D.W., Rowland, A.M., Winer, J. & Ferrara, N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267, 26031\u201326037 (1992).","journal-title":"J. Biol. Chem."},{"key":"BFnm0603669_CR34","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1091\/mbc.4.12.1317","volume":"4","author":"JE Park","year":"1993","unstructured":"Park, J.E., Keller, H.-A. & Ferrara, N. The vascular endothelial growth factor isoforms (VEGF): differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 4, 1317\u20131326 (1993).","journal-title":"Mol. Biol. Cell"},{"key":"BFnm0603669_CR35","doi-asserted-by":"publisher","first-page":"7788","DOI":"10.1074\/jbc.271.13.7788","volume":"271","author":"BA Keyt","year":"1996","unstructured":"Keyt, B.A. et al. The carboxyl-terminal domain (111\u2013165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem. 271, 7788\u20137795 (1996).","journal-title":"J. Biol. Chem."},{"key":"BFnm0603669_CR36","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/8379","volume":"5","author":"P Carmeliet","year":"1999","unstructured":"Carmeliet, P. et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelila growth factor isoforms VEGF164 and VEGF188 . Nat. Med. 5, 495\u2013502 (1999).","journal-title":"Nat. Med."},{"key":"BFnm0603669_CR37","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1101\/gad.242002","volume":"16","author":"C Ruhrberg","year":"2002","unstructured":"Ruhrberg, C. et al. Spatially restricted patterning cues provided by heparin-binding VEGFA control blood vessel branching morphogenesis. Genes Dev. 16, 2684\u20132698 (2002).","journal-title":"Genes Dev."},{"key":"BFnm0603669_CR38","doi-asserted-by":"publisher","first-page":"C1367","DOI":"10.1152\/ajpcell.2001.280.6.C1367","volume":"280","author":"Y Dor","year":"2001","unstructured":"Dor, Y., Porat, R. & Keshet, E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am. J. Physiol. 280, C1367\u2013C1374 (2001).","journal-title":"Am. J. Physiol."},{"key":"BFnm0603669_CR39","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/S0006-2952(02)01168-1","volume":"64","author":"G Semenza","year":"2002","unstructured":"Semenza, G. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol. 64, 993\u2013998 (2002).","journal-title":"Biochem. Pharmacol."},{"key":"BFnm0603669_CR40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/15216540252774757","volume":"52","author":"DR Mole","year":"2001","unstructured":"Mole, D.R., Maxwell, P.H., Pugh, C.W. & Ratcliffe, P.J. Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing. IUBMB Life 52, 43\u201347 (2001).","journal-title":"IUBMB Life"},{"key":"BFnm0603669_CR41","first-page":"2299","volume":"56","author":"G Siemeister","year":"1996","unstructured":"Siemeister, G. et al. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res. 56, 2299\u20132301 (1996).","journal-title":"Cancer Res."},{"key":"BFnm0603669_CR42","doi-asserted-by":"publisher","first-page":"10595","DOI":"10.1073\/pnas.93.20.10595","volume":"93","author":"O Iliopoulos","year":"1996","unstructured":"Iliopoulos, O., Levy, A.P., Jiang, C., Kaelin, W.G. & Goldberg, M.A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA 93, 10595\u201310599 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm0603669_CR43","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"PH Maxwell","year":"1999","unstructured":"Maxwell, P.H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271\u2013275 (1999).","journal-title":"Nature"},{"key":"BFnm0603669_CR44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1006\/scdb.2001.0287","volume":"13","author":"PH Maxwell","year":"2002","unstructured":"Maxwell, P.H. & Ratcliffe, P.J. Oxygen sensors and angiogenesis. Semin. Cell Dev. Biol. 13, 29\u201337 (2002).","journal-title":"Semin. Cell Dev. Biol."},{"key":"BFnm0603669_CR45","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1172\/JCI200318181","volume":"111","author":"M Safran","year":"2003","unstructured":"Safran, M. & Kaelin, W.J. HIF hydroxylation and the mammalian oxygen-sensing pathway. J. Clin Invest. 111, 779\u2013783 (2003).","journal-title":"J. Clin Invest."},{"key":"BFnm0603669_CR46","doi-asserted-by":"publisher","first-page":"25915","DOI":"10.1074\/jbc.270.43.25915","volume":"270","author":"S Grugel","year":"1995","unstructured":"Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B. & Marme, D. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J. Biol. Chem. 270, 25915\u201325919 (1995).","journal-title":"J. Biol. Chem."},{"key":"BFnm0603669_CR47","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1073\/pnas.95.7.3609","volume":"95","author":"F Okada","year":"1998","unstructured":"Okada, F. et al. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor\/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc. Natl. Acad. Sci. USA 95, 3609\u20133614 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm0603669_CR48","first-page":"519","volume":"8","author":"M Shibuya","year":"1990","unstructured":"Shibuya, M. et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogene 8, 519\u2013527 (1990).","journal-title":"Oncogene"},{"key":"BFnm0603669_CR49","first-page":"1677","volume":"6","author":"BI Terman","year":"1991","unstructured":"Terman, B.I. et al. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6, 1677\u20131683 (1991).","journal-title":"Oncogene"},{"key":"BFnm0603669_CR50","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1126\/science.1312256","volume":"255","author":"C de Vries","year":"1992","unstructured":"de Vries, C. et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989\u2013991 (1992).","journal-title":"Science"},{"key":"BFnm0603669_CR51","doi-asserted-by":"publisher","first-page":"23659","DOI":"10.1074\/jbc.272.38.23659","volume":"272","author":"HP Gerber","year":"1997","unstructured":"Gerber, H.P., Condorelli, F., Park, J. & Ferrara, N. Differential transcriptional regulation of the two VEGF receptor genes. Flt-1, but not Flk-1\/KDR, is up-regulated by hypoxia. J. Biol. Chem. 272, 23659\u201323667 (1997).","journal-title":"J. Biol. Chem."},{"key":"BFnm0603669_CR52","doi-asserted-by":"publisher","first-page":"25646","DOI":"10.1016\/S0021-9258(18)47298-5","volume":"269","author":"JE Park","year":"1994","unstructured":"Park, J.E., Chen, H.H., Winer, J., Houck, K.A. & Ferrara, N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1\/KDR. J. Biol. Chem. 269, 25646\u201325654 (1994).","journal-title":"J. Biol. Chem."},{"key":"BFnm0603669_CR53","doi-asserted-by":"publisher","first-page":"11709","DOI":"10.1073\/pnas.95.20.11709","volume":"95","author":"B Olofsson","year":"1998","unstructured":"Olofsson, B. et al. Vascular endothelial growth factor B (VEGFB) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl. Acad. Sci. USA 95, 11709\u201311714 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm0603669_CR54","doi-asserted-by":"publisher","first-page":"10705","DOI":"10.1073\/pnas.90.22.10705","volume":"90","author":"RL Kendall","year":"1993","unstructured":"Kendall, R.L. & Thomas, K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA 90, 10705\u201310709 (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm0603669_CR55","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1002\/j.1460-2075.1996.tb00872.x","volume":"15","author":"T Davis-Smyth","year":"1996","unstructured":"Davis-Smyth, T., Chen, H., Park, J., Presta, L.G. & Ferrara, N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J. 15, 4919\u20134927 (1996).","journal-title":"EMBO J."},{"key":"BFnm0603669_CR56","doi-asserted-by":"publisher","first-page":"26988","DOI":"10.1016\/S0021-9258(18)47116-5","volume":"269","author":"J Waltenberger","year":"1994","unstructured":"Waltenberger, J., Claesson Welsh, L., Siegbahn, A., Shibuya, M. & Heldin, C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269, 26988\u201326995 (1994).","journal-title":"J. Biol. Chem."},{"key":"BFnm0603669_CR57","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/87904","volume":"7","author":"P Carmeliet","year":"2001","unstructured":"Carmeliet, P. et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7, 575\u2013583 (2001).","journal-title":"Nat. Med."},{"key":"BFnm0603669_CR58","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1093\/emboj\/19.15.4064","volume":"19","author":"H Gille","year":"2000","unstructured":"Gille, H. et al. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits VEGF-dependent PI 3 kinase activation and endothelial cell migration. EMBO J. 19, 4064\u20134073 (2000).","journal-title":"EMBO J."},{"key":"BFnm0603669_CR59","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1038\/sj.onc.1201786","volume":"16","author":"Y Maru","year":"1998","unstructured":"Maru, Y., Yamaguchi, S. & Shibuya, M. Flt-1, a receptor for vascular endothelial growth factor, has transforming and morphogenic potentials. Oncogene 16, 2585\u20132595 (1998).","journal-title":"Oncogene"},{"key":"BFnm0603669_CR60","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/376066a0","volume":"376","author":"GH Fong","year":"1995","unstructured":"Fong, G.H., Rossant, J., Gertsenstein, M. & Breitman, M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66\u201370 (1995).","journal-title":"Nature"},{"key":"BFnm0603669_CR61","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1242\/dev.126.13.3015","volume":"126","author":"GH Fong","year":"1999","unstructured":"Fong, G.H., Zhang, L., Bryce, D.M. & Peng, J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development 126, 3015\u20133025 (1999).","journal-title":"Development"},{"key":"BFnm0603669_CR62","doi-asserted-by":"publisher","first-page":"9349","DOI":"10.1073\/pnas.95.16.9349","volume":"4","author":"S Hiratsuka","year":"1998","unstructured":"Hiratsuka, S., Minowa, O., Kuno, J., Noda, T. & Shibuya, M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. USA 4, 9349\u20139354 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm0603669_CR63","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1182\/blood.V87.8.3336.bloodjournal8783336","volume":"87","author":"B Barleon","year":"1996","unstructured":"Barleon, B. et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87, 3336\u20133343 (1996).","journal-title":"Blood"},{"key":"BFnm0603669_CR64","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S1535-6108(02)00153-8","volume":"2","author":"S Hiratsuka","year":"2002","unstructured":"Hiratsuka, S. et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2, 289\u2013300 (2002).","journal-title":"Cancer Cell"},{"key":"BFnm0603669_CR65","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/nm740","volume":"8","author":"K Hattori","year":"2002","unstructured":"Hattori, K. et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat. Med. 8, 841\u2013849 (2002).","journal-title":"Nat. Med."},{"key":"BFnm0603669_CR66","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/nm731","volume":"8","author":"A Luttun","year":"2002","unstructured":"Luttun, A. et al. Revascularization of ischemic tissues by PLGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 8, 831\u2013840 (2002).","journal-title":"Nat. Med."},{"key":"BFnm0603669_CR67","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1126\/science.1079562","volume":"299","author":"J LeCouter","year":"2003","unstructured":"LeCouter, J. et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299, 890\u2013893 (2003).","journal-title":"Science"},{"key":"BFnm0603669_CR68","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/0006-291X(92)90483-2","volume":"187","author":"BI Terman","year":"1992","unstructured":"Terman, B.I. et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187, 1579\u20131586 (1992).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnm0603669_CR69","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/376062a0","volume":"376","author":"F Shalaby","year":"1995","unstructured":"Shalaby, F. et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62\u201366 (1995).","journal-title":"Nature"},{"key":"BFnm0603669_CR70","doi-asserted-by":"publisher","first-page":"6729","DOI":"10.1074\/jbc.270.12.6729","volume":"270","author":"D Guo","year":"1995","unstructured":"Guo, D., Jia, Q., Song, H.Y., Warren, R.S. & Donner, D.B. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J. Biol. Chem. 270, 6729\u20136733 (1995).","journal-title":"J. Biol. Chem."},{"key":"BFnm0603669_CR71","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/S1097-2765(00)80221-X","volume":"4","author":"BP Eliceiri","year":"1999","unstructured":"Eliceiri, B.P. et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell 4, 915\u2013924 (1999).","journal-title":"Mol. Cell"},{"key":"BFnm0603669_CR72","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1038\/sj.onc.1202527","volume":"18","author":"T Takahashi","year":"1999","unstructured":"Takahashi, T., Ueno, H. & Shibuya, M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18, 2221\u20132230 (1999).","journal-title":"Oncogene"},{"key":"BFnm0603669_CR73","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1074\/jbc.M002016200","volume":"276","author":"H Gille","year":"2001","unstructured":"Gille, H. et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific VEGF mutants. J. Biol. Chem. 276, 3222\u20133230 (2001).","journal-title":"J. Biol. Chem."},{"key":"BFnm0603669_CR74","first-page":"2749","volume":"62","author":"A Adini","year":"2002","unstructured":"Adini, A., Kornaga, T., Firoozbakht, F. & Benjamin, L.E. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res. 62, 2749\u20132752 (2002).","journal-title":"Cancer Res."},{"key":"BFnm0603669_CR75","doi-asserted-by":"publisher","first-page":"5761","DOI":"10.1074\/jbc.271.10.5761","volume":"271","author":"S Soker","year":"1996","unstructured":"Soker, S., Fidder, H., Neufeld, G. & Klagsbrun, M. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J. Biol. Chem. 271, 5761\u20135767 (1996).","journal-title":"J. Biol. Chem."},{"key":"BFnm0603669_CR76","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0092-8674(00)81402-6","volume":"92","author":"S Soker","year":"1998","unstructured":"Soker, S., Takashima, S., Miao, H.Q., Neufeld, G. & Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735\u2013745 (1998).","journal-title":"Cell"},{"key":"BFnm0603669_CR77","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S1050-1738(01)00140-2","volume":"12","author":"G Neufeld","year":"2002","unstructured":"Neufeld, G. et al. The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc. Med. 12, 13\u201319 (2002).","journal-title":"Trends Cardiovasc. Med."},{"key":"BFnm0603669_CR78","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.1242\/dev.126.21.4895","volume":"126","author":"T Kawasaki","year":"1999","unstructured":"Kawasaki, T. et al. A requirement for neuropilin-1 in embryonic vessel formation, Development 126, 4895\u20134902 (1999).","journal-title":"Development"},{"key":"BFnm0603669_CR79","doi-asserted-by":"publisher","first-page":"10470","DOI":"10.1073\/pnas.162366299","volume":"99","author":"P Lee","year":"2002","unstructured":"Lee, P. et al. Neuropilin-1 is required for vascular development and is a mediator of VEGF-dependent angiogenesis in zebrafish. Proc. Natl. Acad. Sci. USA 99, 10470\u201310475 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm0603669_CR80","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/380435a0","volume":"380","author":"P Carmeliet","year":"1996","unstructured":"Carmeliet, P. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435\u2013439 (1996).","journal-title":"Nature"},{"key":"BFnm0603669_CR81","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/380439a0","volume":"380","author":"N Ferrara","year":"1996","unstructured":"Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439\u2013442 (1996).","journal-title":"Nature"},{"key":"BFnm0603669_CR82","doi-asserted-by":"publisher","first-page":"E29","DOI":"10.1161\/01.RES.86.2.e29","volume":"86","author":"D Bellomo","year":"2000","unstructured":"Bellomo, D. et al. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ. Res. 86, E29\u2013E35 (2000).","journal-title":"Circ. Res."},{"key":"BFnm0603669_CR83","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1172\/JCI119416","volume":"99","author":"Y Kitamoto","year":"1997","unstructured":"Kitamoto, Y., Tokunaga, H. & Tomita, K. Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis. J. Clin. Invest. 99, 2351\u20132357 (1997).","journal-title":"J. Clin. Invest."},{"key":"BFnm0603669_CR84","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1172\/JCI17423","volume":"111","author":"V Eremina","year":"2003","unstructured":"Eremina, V. et al. Glomerular-specific alterations of VEGFA expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 111, 707\u2013716 (2003).","journal-title":"J. Clin. Invest."},{"key":"BFnm0603669_CR85","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/019262339902700115","volume":"27","author":"AM Ryan","year":"1999","unstructured":"Ryan, A.M. et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol. Pathol. 27, 78\u201386 (1999).","journal-title":"Toxicol. Pathol."},{"key":"BFnm0603669_CR86","first-page":"179","volume-title":"Cartilage: Molecular Aspects","author":"AR Poole","year":"1991","unstructured":"Poole, A.R. The growth plate: cellular physiology, cartilage assembly and mineralization. in Cartilage: Molecular Aspects (eds. Hall, B.K. & Newman, S.A.) 179\u2013211 (CRC Press, Boca Raton, Florida, 1991)."},{"key":"BFnm0603669_CR87","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/9467","volume":"5","author":"HP Gerber","year":"1999","unstructured":"Gerber, H.P. et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 5, 623\u2013628 (1999).","journal-title":"Nat. Med."},{"key":"BFnm0603669_CR88","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1242\/dev.127.7.1445","volume":"127","author":"JJ Haigh","year":"2000","unstructured":"Haigh, J.J., Gerber, H.P., Ferrara, N. & Wagner, E.F. Conditional inactivation of VEGFA in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development 127, 1445\u20131453 (2000).","journal-title":"Development"},{"key":"BFnm0603669_CR89","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1242\/dev.129.8.1893","volume":"129","author":"E Zelzer","year":"2002","unstructured":"Zelzer, E. et al. Skeletal defects in VEGF(120\/120) mice reveal multiple roles for VEGF in skeletogenesis. Development 129, 1893\u20131904 (2002).","journal-title":"Development"},{"key":"BFnm0603669_CR90","first-page":"1385","volume":"78","author":"V Goede","year":"1998","unstructured":"Goede, V., Schmidt, T., Kimmina, S., Kozian, D. & Augustin, H.G. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab. Invest. 78, 1385\u20131394 (1998).","journal-title":"Lab. Invest."},{"key":"BFnm0603669_CR91","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1210\/endo-127-2-965","volume":"127","author":"HS Phillips","year":"1990","unstructured":"Phillips, H.S., Hains, J., Leung, D.W. & Ferrara, N. Vascular endothelial growth factor is expressed in rat corpus luteum. Endocrinology 127, 965\u2013967 (1990).","journal-title":"Endocrinology"},{"key":"BFnm0603669_CR92","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nm0398-336","volume":"4","author":"N Ferrara","year":"1998","unstructured":"Ferrara, N. et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med. 4, 336\u2013340 (1998).","journal-title":"Nat. Med."},{"key":"BFnm0603669_CR93","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1210\/endo.141.3.7369","volume":"141","author":"HM Fraser","year":"2000","unstructured":"Fraser, H.M. et al. Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor. Endocrinology 141, 995\u20131000 (2000).","journal-title":"Endocrinology"},{"key":"BFnm0603669_CR94","first-page":"768","volume":"86","author":"RC Zimmermann","year":"2001","unstructured":"Zimmermann, R.C. et al. Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey. J. Clin. Endocrinol. Metab. 86, 768\u2013772 (2001).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnm0603669_CR95","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/35091000","volume":"412","author":"J LeCouter","year":"2001","unstructured":"LeCouter, J. et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 412, 877\u2013884 (2001).","journal-title":"Nature"},{"key":"BFnm0603669_CR96","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nm0902-913","volume":"8","author":"J LeCouter","year":"2002","unstructured":"LeCouter, J., Lin, R. & Ferrara, N. Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis. Nat. Med. 8, 913\u2013917 (2002).","journal-title":"Nat. Med."},{"key":"BFnm0603669_CR97","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/S0002-9440(10)64322-2","volume":"162","author":"N Ferrara","year":"2003","unstructured":"Ferrara, N. et al. Differential expression of the angiogenic factor genes VEGF and EG-VEGF in normal and polycystic human ovaries. Am. J. Path. 162, 1881\u20131893 (2003).","journal-title":"Am. J. Path."},{"key":"BFnm0603669_CR98","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/362841a0","volume":"362","author":"KJ Kim","year":"1993","unstructured":"Kim, K.J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362, 841\u2013844 (1993).","journal-title":"Nature"},{"key":"BFnm0603669_CR99","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S0092-8674(00)81731-6","volume":"94","author":"D Fukumura","year":"1998","unstructured":"Fukumura, D. et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94, 715\u2013725 (1998).","journal-title":"Cell"},{"key":"BFnm0603669_CR100","first-page":"6253","volume":"60","author":"HP Gerber","year":"2000","unstructured":"Gerber, H.P., Kowalski, J., Sherman, D., Eberhard, D.A. & Ferrara, N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 60, 6253\u20136258 (2000).","journal-title":"Cancer Res."},{"key":"BFnm0603669_CR101","first-page":"6248","volume":"60","author":"Y Tsuzuki","year":"2000","unstructured":"Tsuzuki, Y. et al. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1\u03b1\u2014> hypoxia response element\u2014> VEGF cascade differ entially regulates vascular response and growth rate in tumors, Cancer Res. 60, 6248\u20136252 (2000).","journal-title":"Cancer Res."},{"key":"BFnm0603669_CR102","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S1535-6108(02)00031-4","volume":"1","author":"M Inoue","year":"2002","unstructured":"Inoue, M., Hager, J.H., Ferrara, N., Gerber, H.P. & Hanahan, D. VEGFA has a critical, nonredundant role in angiogenic switching and pancreatic \u03b2 cell carcinogenesis. Cancer Cell. 1, 193\u2013202 (2002).","journal-title":"Cancer Cell."},{"key":"BFnm0603669_CR103","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/35036374","volume":"2","author":"G Bergers","year":"2000","unstructured":"Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2, 737\u2013744 (2000).","journal-title":"Nat. Cell Biol."},{"key":"BFnm0603669_CR104","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1172\/JCI8829","volume":"105","author":"G Klement","year":"2000","unstructured":"Klement, G. et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15\u2013R24 (2000).","journal-title":"J. Clin. Invest."},{"key":"BFnm0603669_CR105","first-page":"5565","volume":"60","author":"CG Lee","year":"2000","unstructured":"Lee, C.G. et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60, 5565\u20135570 (2000).","journal-title":"Cancer Res."},{"key":"BFnm0603669_CR106","first-page":"4593","volume":"57","author":"LG Presta","year":"1997","unstructured":"Presta, L.G. et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593\u20134599 (1997).","journal-title":"Cancer Res."},{"key":"BFnm0603669_CR107","first-page":"5209","volume":"59","author":"M Prewett","year":"1999","unstructured":"Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209\u20135218 (1999).","journal-title":"Cancer Res."},{"key":"BFnm0603669_CR108","first-page":"2178","volume":"60","author":"JM Wood","year":"2000","unstructured":"Wood, J.M. et al. PTK787\/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60, 2178\u20132189 (2000).","journal-title":"Cancer Res."},{"key":"BFnm0603669_CR109","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1073\/pnas.172398299","volume":"99","author":"J Holash","year":"2002","unstructured":"Holash, J. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA 99, 11393\u201311398 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm0603669_CR110","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","volume":"21","author":"F Kabbinavar","year":"2003","unstructured":"Kabbinavar, F. et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21, 60\u201365 (2003).","journal-title":"J. Clin. Oncol."},{"key":"BFnm0603669_CR111","unstructured":"Yang, J.C. et al. A randomized trial of bevacizumab (anti-VEGF antibody) in metastatic renal cancer. N. Engl. J. Med. (in the press)."},{"key":"BFnm0603669_CR112","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00109-002-0397-4","volume":"81","author":"HP Gerber","year":"2003","unstructured":"Gerber, H.P. & Ferrara, N. The role of VEGF in normal and neoplastic hematopoiesis. J. Mol. Med. 81, 20\u201331 (2003).","journal-title":"J. Mol. Med."},{"key":"BFnm0603669_CR113","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1182\/blood.V97.5.1413","volume":"97","author":"BD Smolich","year":"2001","unstructured":"Smolich, B.D. et al. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemi blasts. Blood 97, 1413\u20131421 (2001).","journal-title":"Blood"},{"key":"BFnm0603669_CR114","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1172\/JCI8978","volume":"106","author":"S Dias","year":"2000","unstructured":"Dias, S. et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest. 106, 511\u2013521 (2000).","journal-title":"J. Clin. Invest."},{"key":"BFnm0603669_CR115","first-page":"1625","volume-title":"Pathobiology of Ocular Disease","author":"A Garner","year":"1994","unstructured":"Garner, A. Vascular diseases. in Pathobiology of Ocular Disease 2nd edn. (eds. Garner, A. & Klintworth, G.K.) 1625\u20131710 (Marcel Dekker, New York, 1994)."},{"key":"BFnm0603669_CR116","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello, L.P. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331, 1480\u20131487 (1994).","journal-title":"N. Engl. J. Med."},{"key":"BFnm0603669_CR117","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1001\/archopht.1994.01090230090028","volume":"112","author":"F Malecaze","year":"1994","unstructured":"Malecaze, F. et al. Detection of vascular endothelial growth factor mRNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch. Ophthalmol. 112, 1476\u20131482 (1994).","journal-title":"Arch. Ophthalmol."},{"key":"BFnm0603669_CR118","doi-asserted-by":"publisher","first-page":"10457","DOI":"10.1073\/pnas.92.23.10457","volume":"92","author":"LP Aiello","year":"1995","unstructured":"Aiello, L.P. et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA 92, 10457\u201310461 (1995).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm0603669_CR119","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/archopht.1996.01100130062010","volume":"114","author":"AP Adamis","year":"1996","unstructured":"Adamis, A.P. et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. Ophthalmol. 114, 66\u201371 (1996).","journal-title":"Arch. Ophthalmol."},{"key":"BFnm0603669_CR120","first-page":"855","volume":"37","author":"PF Lopez","year":"1996","unstructured":"Lopez, P.F., Sippy, B.D., Lambert, H.M., Thach, A.B. & Hinton, D.R. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. 37, 855\u2013868 (1996).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"BFnm0603669_CR121","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1006\/jmbi.1999.3192","volume":"293","author":"Y Chen","year":"1999","unstructured":"Chen, Y. et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J. Mol. Biol. 293, 865\u2013881 (1999).","journal-title":"J. Mol. Biol."},{"key":"BFnm0603669_CR122","doi-asserted-by":"publisher","first-page":"20556","DOI":"10.1074\/jbc.273.32.20556","volume":"273","author":"J Ruckman","year":"1998","unstructured":"Ruckman, J. et al. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273, 20556\u201320567 (1998).","journal-title":"J. Biol. Chem."},{"key":"BFnm0603669_CR123","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1001\/archopht.120.3.338","volume":"120","author":"MG Krzystolik","year":"2002","unstructured":"Krzystolik, M.G. et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol. 120, 338\u2013346 (2002).","journal-title":"Arch. Ophthalmol."},{"key":"BFnm0603669_CR124","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/1523-1747.ep12312542","volume":"105","author":"M Detmar","year":"1995","unstructured":"Detmar, M. et al. Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J. Invest. Dermatol. 105, 44\u201350 (1995).","journal-title":"J. Invest. Dermatol."},{"key":"BFnm0603669_CR125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1523-1747.1998.00262.x","volume":"111","author":"M Detmar","year":"1998","unstructured":"Detmar, M. et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J. Invest. Dermatol. 111, 1\u20136 (1998).","journal-title":"J. Invest. Dermatol."},{"key":"BFnm0603669_CR126","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0092-8674(03)00154-5","volume":"112","author":"T Cramer","year":"2003","unstructured":"Cramer, T. HIF1\u03b1 is essential for myeloid cell-mediated inflammation. Cell 112, 645\u2013657 (2003).","journal-title":"Cell"},{"key":"BFnm0603669_CR127","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1161\/01.STR.27.10.1865","volume":"27","author":"Z Kovacs","year":"1996","unstructured":"Kovacs, Z., Ikezaki, K., Samoto, K., Inamura, T. & Fukui, M. VEGF and flt. Expression time kinetics in rat brain infarct. Stroke 27, 1865\u20131872 (1996).","journal-title":"Stroke"},{"key":"BFnm0603669_CR128","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1172\/JCI8218","volume":"104","author":"N van Bruggen","year":"1999","unstructured":"van Bruggen, N. et al. VEGF antagonism reduces edema formation and tissue damage after ischemia\/reperfusion injury in the mouse brain. J. Clin. Invest. 104, 1613\u20131620 (1999).","journal-title":"J. Clin. Invest."},{"key":"BFnm0603669_CR129","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/84675","volume":"7","author":"R Paul","year":"2001","unstructured":"Paul, R. et al. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat. Med. 7, 222\u2013227 (2001).","journal-title":"Nat. Med."},{"key":"BFnm0603669_CR130","first-page":"436","volume-title":"Reproductive Endocrinology","author":"SSC Yen","year":"1999","unstructured":"Yen, S.S.C. Polycystic ovary syndrome (hyperandrogenic chronic anovulation). in Reproductive Endocrinology (eds. Yen, S.S.C., Jaffe, R.B. & Barbieri, R.L.) 436\u2013478 (W.B. Saunders, Philadelphia, 1999)."},{"key":"BFnm0603669_CR131","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1172\/JCI118815","volume":"98","author":"J McLaren","year":"1996","unstructured":"McLaren, J. et al. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J. Clin. Invest. 98, 482\u2013489 (1996).","journal-title":"J. Clin. Invest."},{"key":"BFnm0603669_CR132","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1172\/JCI17189","volume":"111","author":"SE Maynard","year":"2003","unstructured":"Maynard, S.E. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649\u2013658 (2003).","journal-title":"J. Clin. Invest."},{"key":"BFnm0603669_CR133","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrc905","volume":"2","author":"R Kerbel","year":"2002","unstructured":"Kerbel, R. & Folkman, J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2, 727\u2013739 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnm0603669_CR134","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1161\/01.CIR.0000061911.47710.8A","volume":"107","author":"TD Henry","year":"2003","unstructured":"Henry, T.D. et al. The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 107, 1359\u20131365 (2003).","journal-title":"Circulation"},{"key":"BFnm0603669_CR135","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1006\/mthe.2002.0638","volume":"6","author":"K Makinen","year":"2002","unstructured":"Makinen, K. et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol. Ther. 6, 127\u2013133 (2002).","journal-title":"Mol. Ther."},{"key":"BFnm0603669_CR136","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1093\/emboj\/21.8.1939","volume":"21","author":"Y Dor","year":"2002","unstructured":"Dor, Y. et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 21, 1939\u20131947 (2002).","journal-title":"EMBO J."},{"key":"BFnm0603669_CR137","doi-asserted-by":"publisher","first-page":"9656","DOI":"10.1073\/pnas.152324099","volume":"99","author":"J Street","year":"2002","unstructured":"Street, J. et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc. Natl. Acad. Sci. USA 99, 9656\u20139661 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nm0603-669.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nm0603-669","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nm0603-669.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:36Z","timestamp":1650326436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm0603-669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6,1]]},"references-count":137,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,6,1]]}},"alternative-id":["BFnm0603669"],"URL":"https:\/\/doi.org\/10.1038\/nm0603-669","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6,1]]}}}